Antibiotic resistance—What’s dosing got to do with it?
Top Cited Papers
- 1 August 2008
- journal article
- review article
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 36 (8) , 2433-2440
- https://doi.org/10.1097/ccm.0b013e318180fe62
Abstract
This review seeks to identify original research articles that link antibiotic dosing and the development of antibiotic resistance for different antibiotic classes. Using this data, we seek to apply pharmacodynamic principles to assist clinical practice for suppressing the emergence of resistance. Concepts such as mutant selection window and mutant prevention concentration will be discussed. PubMed, EMBASE, and the Cochrane Controlled Trial Register. All articles that related antibiotic doses and exposure to the formation of antibiotic resistance were reviewed. The escalation of antibiotic resistance continues worldwide, most prominently in patients in intensive care units. Data are emerging from in vitro and in vivo studies that suggest that inappropriately low antibiotic dosing may be contributing to the increasing rate of antibiotic resistance. Fluoroquinolones have widely been researched and publications on other antibiotic classes are emerging. Developing dosing regimens that adhere to pharmacodynamic principles and maximize antibiotic exposure is essential to reduce the increasing rate of antibiotic resistance. Antibiotic dosing must aim to address not only the bacteria isolated, but also the most resistant subpopulation in the colony, to prevent the advent of further resistant infections because of the inadvertent selection pressure of current dosing regimens. This may be achieved by maximizing antibiotic exposure by administering the highest recommended dose to the patient.Keywords
This publication has 83 references indexed in Scilit:
- Is continuous infusion ceftriaxone better than once-a-day dosing in intensive care? A randomized controlled pilot studyJournal of Antimicrobial Chemotherapy, 2006
- Selection of ciprofloxacin resistance in Escherichia coli in an in vitro kinetic model: relation between drug exposure and mutant prevention concentrationJournal of Antimicrobial Chemotherapy, 2006
- Bad Bugs Need Drugs: An Update on the Development Pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2006
- Pharmacodynamic Model To Describe the Concentration-Dependent Selection of Cefotaxime-ResistantEscherichia coliAntimicrobial Agents and Chemotherapy, 2005
- Evolution and spread of antibiotic resistanceJournal of Internal Medicine, 2002
- Continuous versus Intermittent Infusion of Vancomycin in Severe Staphylococcal Infections: Prospective Multicenter Randomized StudyAntimicrobial Agents and Chemotherapy, 2001
- In Vitro Development of Resistance to Ofloxacin and Doxycycline in Bacillus anthracis Sterne Antimicrobial Agents and Chemotherapy, 2000
- A Meta-Analysis of Extended-Interval Dosing Versus Multiple Daily Dosing of AminoglycosidesClinical Infectious Diseases, 1997
- A Meta-Analysis of the Relative Efficacy and Toxicity of Single Daily Dosing Versus Multiple Daily Dosing of AminoglycosidesClinical Infectious Diseases, 1997
- Resistance to Nalidixic AcidJAMA, 1976